MedTrace Logo

A Dose Range-Finding Study to Assess the Efficacy and Safety of Multiple Dose Levels of AZD8630 in Adults With Uncontrolled Asthma at Risk of Exacerbations

NCT06529419 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 537

Last updated 2026-03-02

No results posted yet for this study

Summary

A dose range-finding study to assess the efficacy and safety of multiple dose levels of AZD8630 administered via a dry powder inhaler in adults with uncontrolled asthma at risk of exacerbations, receiving medium -to -high dose inhaled corticosteroid (ICS)/long-acting β2-agonist (LABA).

Conditions

Interventions

DRUG

AZD8630

The drug will be administered by inhalation

DRUG

Placebo

The placebo will be administered by inhalation

DEVICE

Inhaler

The drug/placebo will be administered by inhalation using the inhaler

Sponsors & Collaborators

Principal Investigators

  • Njira Lugogo · Univeristy of Michigan Hospital, Ann Arbor, MI, US

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-08-30
Primary Completion
2026-02-04
Completion
2026-02-04
FDA Drug
Yes
FDA Device
Yes

Countries

  • United States
  • Argentina
  • Belgium
  • Chile
  • China
  • Czechia
  • Denmark
  • France
  • Germany
  • Hong Kong
  • Israel
  • Italy
  • Japan
  • Mexico
  • Netherlands
  • Slovakia
  • South Africa
  • South Korea
  • Spain
  • Taiwan
  • Turkey (Türkiye)
  • Ukraine
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06529419 on ClinicalTrials.gov